Recurrent Rare Copy Number Variants Increase Risk for Esotropia

AbstractGermline copy number variants (CNVs) increase risk for many diseases, yet detection of CNVs and quantifying their contribution to disease risk in large-scale studies is challenging. We developed an approach called CNPBayes to identify latent batch effects, to provide probabilistic estimates of integer copy number across the estimated batches, and to fully integrate the copy number uncertainty in the association model for disease. We demonstrate this approach in a Pancreatic Cancer Case Control study of 7,598 participants where the major sources of technical variation were not captured by study site and varied across the genome. Candidate associations aided by this approach include deletions of 8q24 near regulatory elements of the tumor oncogene MYC and of Tumor Supressor Candidate 3 (TUSC3). This study provides a robust Bayesian inferential framework for estimating copy number and evaluating the role of copy number in heritable diseases.

Download Full-text

The Role of Copy Number Variation in Psychiatric Disorders

Psychiatric Genetics ◽

10.1093/med/9780190221973.003.0006 ◽

2018 ◽

pp. 84-95

Author(s):

Elliott Rees ◽

George Kirov

Keyword(s):

Autism Spectrum Disorders ◽

Copy Number ◽

Selection Pressure ◽

Copy Number Variants ◽

Autism Spectrum ◽

High Odds ◽

Strong Selection ◽

Increase Risk ◽

Number Variation

Copy number variants (CNVs) are deletions, duplications, inversions, or translocations of large DNA segments. They can play a significant role in human disease. Thirteen CNVs have received strong statistical support for involvement in schizophrenia. They are all rare in cases (<1%), much rarer among controls, and have high odds ratios (ORs) for causing disease. The same CNVs also increase risk for autism spectrum disorders, developmental delay, and medical/physical comorbidities. The penetrance of these CNVs for any disorder is relatively high, ranging from 10% for 15q11.2 deletions to nearly 100% for deletions at 22q11.2. Strong selection pressure operates against carriers of these CNVs. Most of these are formed by non-allelic homologous recombination (NAHR), which leads to high mutation rates, thus maintaining the rates of these CNVs in the general population, despite the strong selection forces.

Download Full-text

Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome

Neuron ◽

10.1016/j.neuron.2017.06.010 ◽

2017 ◽

Vol 94 (6) ◽

pp. 1101-1111.e7 ◽

Cited By ~ 68

Author(s):

Alden Y. Huang ◽

Dongmei Yu ◽

Lea K. Davis ◽

Jae Hoon Sul ◽

Fotis Tsetsos ◽

...

Keyword(s):

Tourette Syndrome ◽

Copy Number ◽

Copy Number Variants ◽

Increase Risk

Download Full-text

Rare copy number variants in NRXN1 and CNTN6 increase risk for Tourette syndrome

10.1101/062471 ◽

2016 ◽

Cited By ~ 3

Author(s):

Alden Y. Huang ◽

Dongmei Yu ◽

Lea K. Davis ◽

Jae-Hoon Sul ◽

Fotis Tsetsos ◽

...

Keyword(s):

Tourette Syndrome ◽

Copy Number ◽

Genetic Architecture ◽

Structural Variation ◽

Copy Number Variants ◽

European Ancestry ◽

Genome Wide ◽

Snp Microarrays ◽

Increase Risk ◽

Increase In Risk

Tourette syndrome (TS) is highly heritable, although identification of its underlying genetic cause(s) has remained elusive. We examined a European ancestry sample composed of 2,435 TS cases and 4,100 controls for copy-number variants (CNVs) using SNP microarrays and identified two genome-wide significant loci that confer a substantial increase in risk for TS (NRXN1, OR=20.3, 95%CI [2.6-156.2], p=6.0 × 10−6; CNTN6, OR=10.1, 95% CI [2.3-45.4], p=3.7 × 10−5). Approximately 1% of TS cases carried one of these CNVs, indicating that rare structural variation contributes significantly to the genetic architecture of TS.

Download Full-text

Understanding Schizophrenia: Genetic Causes and Treatment

Current Neuropsychiatry and Clinical Neuroscience Reports ◽

10.33702/cncnr.2019.1.1.2 ◽

2019 ◽

Vol 1 (1) ◽

pp. 6-12

Author(s):

Fatima Javeria ◽

Shazma Altaf ◽

Alishah Zair ◽

Rana Khalid Iqbal

Keyword(s):

Copy Number ◽

Drug Targets ◽

Disease Risk ◽

Mental Disease ◽

Copy Number Variants ◽

Aminobutyric Acid ◽

Epigenetic Mechanisms ◽

Gamma Aminobutyric Acid ◽

Wide Range ◽

Severe Mental Disease

Schizophrenia is a severe mental disease. The word schizophrenia literally means split mind. There are three major categories of symptoms which include positive, negative and cognitive symptoms. The disease is characterized by symptoms of hallucination, delusions, disorganized thinking and speech. Schizophrenia is related to many other mental and psychological problems like suicide, depression, hallucinations. Including these, it is also a problem for the patient’s family and the caregiver. There is no clear reason for the disease, but with the advances in molecular genetics; certain epigenetic mechanisms are involved in the pathophysiology of the disease. Epigenetic mechanisms that are mainly involved are the DNA methylation, copy number variants. With the advent of GWAS, a wide range of SNPs is found linked with the etiology of schizophrenia. These SNPs serve as ‘hubs’; because these all are integrating with each other in causing of schizophrenia risk. Until recently, there is no treatment available to cure the disease; but anti-psychotics can reduce the disease risk by minimizing its symptoms. Dopamine, serotonin, gamma-aminobutyric acid, are the neurotransmitters which serve as drug targets in the treatment of schizophrenia. Due to the involvement of genetic and epigenetic mechanisms, drugs available are already targeting certain genes involved in the etiology of the disease.

Download Full-text